Taste Note - Amazon Management Best Sellers
How the Mighty Fall: The Five Stages of Corporate Decline
A Kurums Book Taste review of How the Mighty Fall for boards and executives who want to detect decline while it is still cheap to reverse.
Why this book fits Kurums
Companies rarely die of one blow; they descend through stages, and the early ones look like success. Collins studied eleven once-great companies that fell and mapped a five-stage pathology - hubris born of success, undisciplined pursuit of more, denial of risk and peril, grasping for salvation, capitulation - with the unnerving finding that a company can be deep into stage three while posting record results.
For the Kurums Corporate Governance audience this is the monitoring framework boards lack: financial dashboards report decline only at stage four, when options have collapsed. The book's markers - arrogant neglect of the core business, growth beyond the ability to staff it, blaming external factors, betting on a savior CEO - are observable in the boardroom years earlier, if someone is assigned to look.
What the book argues
The first argument is that decline is self-inflicted and staged, not sudden or external. Stage one, hubris born of success, is entitlement: the company treats success as deserved rather than contingent, and neglects the primary flywheel while reaching for the next thing. Stage two, undisciplined pursuit of more, is overreach - growth past the ability to fill key seats with the right people, leaps outside what the company can be best at. Circuit City and Ames serve as autopsies: the wounds were ambition, applied without discipline, while the numbers still applauded.
The second argument is that stage three - denial of risk and peril - is where governance either works or fails, because it is the last stage where the company is still strong. The markers are behavioral: amplifying positive data and discounting negative, big bets made without empirical validation, blaming externals, reorganizing instead of confronting facts, and the erosion of what Collins calls productive paranoia. His diagnostic question for leadership teams - has the proportion of key seats filled with the right people gone up or down? - is answerable in any board cycle, which is precisely why he aims the book at directors.
The final argument is double-edged: grasping for salvation kills faster than the disease, yet decline is reversible at every stage short of capitulation. Stage-four companies reach for dramatic rescues - the visionary outsider CEO, the transformational acquisition, the bet-the-company pivot - and each unvalidated leap burns the remaining runway. The recoveries Collins documents - Nucor, Nordstrom, IBM under Gerstner, Xerox under Mulcahy - share the opposite shape: a return to disciplined people, disciplined thought, and disciplined action, usually led from inside the values if not inside the company. Hope, the book concludes, is a strategy only when it is boring.
Key ideas, translated to your desk
Record results can hide stage three
Financial dashboards lag the pathology by years. Add behavioral markers - denial patterns, unvalidated bets, externalized blame - to the board's standing risk review.
Track the right-people ratio
Collins's single best indicator: is the share of key seats held by the right people rising or falling? Measure it like revenue, because it predicts revenue.
Saviors accelerate the fall
When a declining company bets on a dramatic outsider or a transformational deal, it is usually in stage four. The recoveries were disciplined and dull - budget for that instead.
Use it at work
- Add a five-stages review to the board calendar annually: score the company against each stage's markers, in writing.
- Compute the right-people ratio for your top 20 seats and trend it quarter over quarter.
- Institute a validation rule: no bet above a set size without empirical confirmation of the underlying assumption.
- When results are at records, commission the stage-one audit - entitlement language, neglected core, growth beyond staffing - precisely because no one wants to.
Read it if
- You govern or lead a successful company - the book is most useful before symptoms.
- You suspect your organization is explaining away bad data and want a structured test.
- You are weighing a savior hire or rescue acquisition and need the base rates.
You can skip it if
- You run an early-stage startup - decline-stage pathology is not your current disease.
- You want deep quantitative method; this is a monograph built on eleven paired cases.
- You have read Good to Great recently and only want new concepts - the frameworks rhyme deliberately.
This book appears in
Curated Tasting Menus that chain this title into a reading route.
Discover more from Kurums | Business Intelligence
Subscribe to get the latest posts sent to your email.